SS18 and neoplasm: Furthermore, on staining for the SS18::SSX fusion specifically obtained from in vivo tumor sections, we observed that TAK-981 treated tumors had a significant decrease in the percentage of cells with high SS18::SSX expression as assessed by immunohistochemistry compared to vehicle treated mice (Fig. 7R,S).